Nektar Therapeutics NKTR

NAS: NKTR | ISIN: US6402681083 28/09/2026

60,40 USD (+5,85%)

(+5,85%) 28/09/2026

Grafiek Nektar Therapeutics

Grafiek Nektar Therapeutics

1 dag1d 5,85%
1 week1w -0,93%
1 maand1m -15,38%
3 maanden3m -7,63%
6 maanden6m -7,43%
1 jaar1j 2,51%
5 jaar5j 236,87%

Nektar Therapeutics in het nieuws

Toon enkel gratis nieuws

28 september 2026 · Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026 · Persbericht

25 september 2026 · Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

28 augustus 2026 · Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

25 augustus 2026 · Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis · Persbericht

13 augustus 2026 · Nektar Therapeutics Announces Second Quarter 2026 Financial Results · Persbericht

29 juli 2026 · Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets · Persbericht

24 juli 2026 · Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

21 juli 2026 · Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis · Persbericht

26 juni 2026 · Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

3 juni 2026 · Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

Profiel Nektar Therapeutics

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.nektar.com

Hoofdzetel: San Francisco, California Verenigde Staten

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe